We involve and support the patient communities we serve.
We begin by listening, to understand the needs and concerns of patients, family members and patient advocates. We provide disease education materials and resources for patient communities.
We aim to enhance health and improve lives for patients with rare diseases and common diseases that have a genetic component. We do not settle for the status quo; we interfere with disease.
We create new medicines with urgency, discipline and vigor. We recognize the importance of real-life experiences and include physicians and patients early in the drug development process. The patient perspective helps guide and shape our clinical development programs.
Beyond drug development, we support the needs of patients, families and patient advocates with updates on our drug development programs, partnerships with advocacy and patient education and access to resources. Together, we share a common commitment of improving the lives of everyone affected by these devastating diseases.
Please see below for the disease states being studied by Dicerna and the development programs underway at the company.
Diseases being studied
Primary Hyperoxaluria (PH) Types 1, 2 and 3
Chronic Hepatitis B Virus (HBV) Infection
Alpha-1 Antitrypsin (A1AT) Deficiency-Associated Liver Disease
Programs in development
Nedosiran (formerly DCR-PHXC) for PH Types 1, 2, and 3 (PHYOX™)
DCR-HBVS for Chronic HBV Infection
DCR-A1AT for A1AT Deficiency-Associated Liver Disease
If you have any questions about any of the development programs at Dicerna, please feel free to send an email to email@example.com.
If you are interested in learning about our activities within the patient community, please contact firstname.lastname@example.org. By providing your information, you agree to allow Dicerna to collect the name and email address provided and to be contacted by Dicerna and its partners using this information.